title: TREATMENT OF METABOLIC ALTERATIONS IN POLYCYSTIC OVARY SYNDROME.
abstract: Polycystic ovary syndrome is a common endocrinopathy characterized by oligo ovulation or anovulation, signs of androgen excess and multiple small ovarian cysts. It includes various metabolic abnormalities: insulin resistance, hyperinsulinemia, impaired glucose tolerance, visceral obesity, inflammation and endothelial dysfunction, hypertension and dyslipidemia. All these metabolic abnormalities have long-term implications. Treatment should be individualized and must not address a single sign or symptom. Studies are still needed to determine the benefits and the associated risks of the medication now available to practitioners.
authors.forename: Ioana
authors.initials: I
authors.lastname: Păvăleanu
authors.forename: D
authors.initials: D
authors.lastname: Gafiţanu
authors.forename: Diana
authors.initials: D
authors.lastname: Popovici
authors.forename: Letiţia Doina
authors.initials: LD
authors.lastname: Duceac
authors.forename: Maricica
authors.initials: M
authors.lastname: Păvăleanu
mesh_terms: D000726:Androgen Antagonists / Q000008:administration & dosage*; D015992:Body Mass Index; D003271:Contraceptive Agents, Female / Q000008:administration & dosage*; D050171:Dyslipidemias / Q000378:metabolism; D005260:Female; D018149:Glucose Intolerance / Q000378:metabolism; D006801:Humans; D006946:Hyperinsulinism / Q000378:metabolism; D006973:Hypertension / Q000378:metabolism; D007333:Insulin Resistance; D056128:Obesity, Abdominal / Q000378:metabolism*; D011085:Polycystic Ovary Syndrome / Q000378:metabolism* / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists; D003271:Contraceptive Agents, Female